Lyell Immunopharma (NASDAQ:LYEL) CEO Lynn Seely Sells 438 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely sold 438 shares of the stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $23.12, for a total transaction of $10,126.56. Following the completion of the transaction, the chief executive officer directly owned 81,721 shares in the company, valued at $1,889,389.52. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Lyell Immunopharma Stock Performance

LYEL opened at $24.34 on Thursday. The business’s 50-day simple moving average is $27.98 and its 200-day simple moving average is $19.60. Lyell Immunopharma, Inc. has a one year low of $7.65 and a one year high of $45.00. The stock has a market capitalization of $516.98 million, a P/E ratio of -1.06 and a beta of -0.14.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.81) by $0.68. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.01 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%. On average, equities research analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Analyst Ratings Changes

LYEL has been the subject of several recent research reports. HC Wainwright upgraded shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and increased their target price for the stock from $20.00 to $45.00 in a research note on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $45.00.

Institutional Trading of Lyell Immunopharma

Several hedge funds have recently modified their holdings of the business. ARCH Venture Management LLC grew its holdings in Lyell Immunopharma by 51.5% during the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock worth $44,807,000 after acquiring an additional 938,438 shares during the period. Vanguard Group Inc. grew its stake in shares of Lyell Immunopharma by 76.0% during the 3rd quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock worth $12,651,000 after purchasing an additional 336,378 shares during the period. Acadian Asset Management LLC increased its holdings in shares of Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after purchasing an additional 443,614 shares in the last quarter. Foresite Capital Management V LLC lifted its stake in shares of Lyell Immunopharma by 17.3% in the third quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company’s stock valued at $7,748,000 after purchasing an additional 70,426 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after buying an additional 154,327 shares in the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.